4 Drug Interactions and Obstetric Anesthesia Τ

Total Page:16

File Type:pdf, Size:1020Kb

4 Drug Interactions and Obstetric Anesthesia Τ 4 Drug Interactions and Obstetric Anesthesia ᭢ Drugs Used for Maternal and Fetal Indications Drugs Used for Maternal Indications Antibiotics Antiepileptic Drugs Enzyme Induction Sympathomimetic Drugs Sympathetic nervous system agonist drugs Antiasthmatic Drugs Xanthine derivatives Sympathomimetic drugs Corticosteroids Histamine H2 Receptor Blockers Psychotropic Agents Phenothiazine, thioxanthenes, and butyrophenones Tricyclic antidepressants Monoamine oxidase inhibitors Lithium carbonate The serotonin syndrome Anesthetic implications Tocolytic Drugs Magnesium sulfate b-Mimetic drugs Calcium channel blockers Prostaglandin inhibitors Hypotensive Drugs Hydralazine Nitroglycerin Nitroprusside Trimethaphan Uterotonic Agents Oxytocin Ergot alkaloids Prostaglandin Local Anesthetics Narcotics Anti-fungal drugs Drugs Used for Fetal Indications DRUG INTERACTIONS AND OBSTETRIC INTERACTIONS 39 Drugs Used for Maternal and Fetal Indications Newer pharmacological agents are being used more fre- quently for the treatment of maternal and fetal pathological states. Obstetric anesthesiologists should be aware of the inter- actions of maternally administered drugs with anesthetic agents and techniques. Drugs Used for Maternal Indications Antibiotics Rarely, parturients may receive antibiotics for various disease processes. Most of the antibiotics will prolong the effect of nondepolarizing muscle relaxants, but prolongation of depolarizing muscle relaxants has also been observed (Table 4-1).1 The mechanism of this phenomenon is unknown. Antagonism of this action by neostigmine and pyridostigmine is found to be unpredictable; however, neuromuscular block- ade from antibiotics could be reversed predictably by 4- aminopyridine.2 Interestingly, the neuromuscular blocking action of the local anesthetic lidocaine is found to be exag- gerated in the presence of neuromuscular blocking drugs and aminoglycoside antibiotics.3 Antiepileptic Drugs Parturients may be taking antiepileptic drugs when they arrive in the hospital for labor and delivery. The common antiepileptic drugs at the present time include phenytoin, phe- nobarbital, benzodiazepines, and valproic acid. The pharma- cokinetics of most of the antiepileptic drugs are altered during pregnancy. Parturients need higher amounts of antiepileptic drugs because of increased volume of distribution; hence mea- surement of the plasma concentration is important. Most of these drugs are metabolized in the liver and thus can interfere with the biotransformation of other drugs. The duration of action of the drugs, which are mainly metabolized by the liver, can be prolonged in parturients who are receiving antiepileptic drugs. These drugs also cross the placenta and can thus 40 D Table 4-1. Interaction of Antibiotics, Muscle Relaxants, Neostigmine, and Calcium RUG Neuromuscular Block Neuromuscular Block Increase in From Antibiotic and I From Antibiotic Alone Neuromuscular d-Tubocurarine NTERACTIONS AND Antagonized by Block of Antagonized by Neostigmine Calcium d-Tubocurarine Succinylcholine Neostigmine Calcium Neomycin Sometimes Sometimes Yes Yes Usually Usually Streptomycin Sometimes Sometimes Yes Yes Usually Usually Gentamicin Sometimes Yes† Yes ‡ Sometimes Yes† Kanamycin Sometimes Sometimes Yes Yes Sometimes Sometimes Paromomycin Yes† Yes† Yes ‡ Yes† Yes† † † ‡ † † O Viomycin Yes Yes Yes Yes Yes BSTETRIC Polymyxin A No No Yes ‡ No No Polymyxin B No§ No Yes Yes No§ No Colistin No Sometimes Yes Yes No Sometimes Tetracycline No ‡ Yes No Partially Partially Lincomycin Partially Partially Yes ‡ Partially Partially A NESTHESIA Clindamycin Partially Partially Yes ‡ Partially Partially From Smith NT, Corbascio AN (eds): Drug Interactions in Anesthesia. Philadelphia, Lea & Febiger, 1986. Used by permission. † In spite of this, difficulty with antagonizing the block from these antibiotics is still likely to occur. ‡ Not studied. §Block augmented by neostigmine. DRUG INTERACTIONS AND OBSTETRIC INTERACTIONS 41 interfere with the synthesis of vitamin K-dependent clotting factors in the fetal liver. Hence, careful observation of the neonate is absolutely essential. Regional anesthesia should be the anesthetic technique of choice because there is evidence that a local anesthetic like lidocaine can be an effective anti- convulsant in therapeutic doses.4 If general anesthesia is indi- cated, the use of enflurane should be avoided because of its epileptogenic property.5 Enzyme Induction Enzyme induction is an adaptive response associated with accumulation of specific mRNAs and increased expression of the associated enzyme system. Oxidative metabolism is cat- alyzed by the P450 enzyme system. P450 enzymes have been grouped into three families: CYP1, CYP2, and CYP3. Several medications selectively induce specific families of the P450 enzyme system. Rifampicin decreased concentration of mida- zolam; its elimination half-life was also reduced.6 Sympathomimetic Drugs Pregnant women may use both sympathetic nervous system agonist and antagonist drugs for either therapeutic or recre- ational reasons. Sympathetic nervous system antagonists are used for the treatment of hypertension; a-Methyldopa, reser- pine, and guanethidine have been used in parturients. Deple- tion of norepinephrine is possible6a in such a situation, and indirect-acting agonists like ephedrine may be ineffective fol- lowing hypotension. Direct-acting agonists like phenylephrine may be indicated in such a situation. Besides these antagonist agents, b-receptor antagonist drugs like propranolol can be used for therapeutic reasons. If the parturient is taking pro- pranolol, medications that increase airway resistance, such as large doses of morphine or prostaglandin F2a (PCF2a) (Prostin), should be used cautiously. Calcium channel block- ers with negative inotropic effects can exaggerate the depres- sant effect of propranolol. Propranolol will cross the placenta and can cause fetal bradycardia and hypoglycemia. Auto- 42 DRUG INTERACTIONS AND OBSTETRIC ANESTHESIA nomic ganglionic blocking drugs like trimethaphan camsylate (Arfonad) are used occasionally to treat hypertension. Because this drug is destroyed by cholinesterase, which is also respon- sible for the metabolism of succinylcholine, a prolonged neu- romuscular block has been described following the use of Arfonad and succinylcholine.7 A few words of caution must be mentioned in using beta blockers such as esmolol. Severe fetal bradycardia has been described when esmolol was given to the mother. The proposed mechanisms include (1) large pla- cental transfer and (2) more beta-specific medications have unrestricted alpha constriction of the uterine blood vessels. Sympathetic Nervous System Agonist Drugs Two drugs in this group that are used recreationally are worth mentioning: 1. Amphetamine is a central nervous system (CNS) stimulant. A new smoked form, “ice,” that produces a “high” of long duration is popular in Hawaii and on the West Coast of the United States. The minimum alveolar concentration is increased in parturients who are addicted to ampheta- mines. Higher doses of narcotics and inhalational anesthetics may be needed for general anesthesia.8 Vaso- pressors, both direct and indirect acting, should be used carefully for the treatment of hypotension. 2. Cocaine is one of the commonly used recreational agents at the present time. It blocks the presynaptic uptake of nor- epinephrine, serotonin, and dopamine. Chronic use will a decrease 2-adrenergic- and presynaptic cholinergic medi- ated norepinephrine release.9 Cocaine is metabolized by cholinesterase and can affect the metabolism of 2-chloro- procaine. Ketamine or excessive catecholamines can cause severe hypertension and myocardial infarction. Tachycar- dia following cocaine use should be treated with labetalol because pure b-adrenergic agents will have unopposed a-adrenergic activity with associated hypertension.10 Calcium channel blockers will also have unopposed action. Decreased pseudocholinesterase levels may prolong the duration of action of succinylcholine. DRUG INTERACTIONS AND OBSTETRIC INTERACTIONS 43 Antiasthmatic Drugs Xanthine Derivatives Xanthine derivatives such as theophylline and amino- phylline may be associated with different drug interactions. Cimetidine has been observed to slow down the elimination of theophylline.11 If general anesthesia is indicated, ketamine should be used carefully because the combination of ketamine and aminophylline can cause significant lowering of the seizure threshold.12 Methylxanthines are associated with the release of endogenous catecholamines; hence halothane can induce dysrhythmias. This problem can be exaggerated if the parturient receives ephedrine13 or epinephrine at the same time. Theophylline can antagonize a nondepolarizing muscle- relaxant block.14 The mechanism is unknown. Pancuronium should be used cautiously because of the possibility of supraventricular tachycardia.15 Sympathomimetic Drugs See the later section “Sympathomimetic Amines.” Corticosteroids Corticosteroids have been observed to alter the disposition of theophylline. The intravenous administration of large doses of corticosteroids was associated with a twofold increase in serum levels of theophylline in patients who were receiving a theophylline infusion.16 Histamine H2 Receptor Blockers The use of H2 receptor blockers has become a common practice before cesarean section. Both cimetidine and raniti- dine have been used as premedicant agents. Cimetidine binds to the hepatic microsomal cytochrome P-450 system. Cimeti- dine as well
Recommended publications
  • E001466.Full.Pdf
    Editorial BMJ Glob Health: first published as 10.1136/bmjgh-2019-001466 on 11 April 2019. Downloaded from WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? Joshua P Vogel, 1,2 Myfanwy Williams,3 Ioannis Gallos,4 Fernando Althabe,1 Olufemi T Oladapo1 To cite: Vogel JP, THE GLOBAL BURDEN OF POSTPARTUM trials of tranexamic acid for PPH treatment Williams M, Gallos I, et al. HAEMORRHAGE and a heat-stable formulation of carbetocin WHO recommendations on 6–12 uterotonics for postpartum Obstetric haemorrhage, especially post- for PPH prevention. The increasing haemorrhage prevention: partum haemorrhage (PPH), was responsible number of PPH prevention and management what works, and which for more than a quarter of the estimated 303 options makes it challenging for providers one?BMJ Glob Health 000 maternal deaths that occurred globally in and health system stakeholders to choose 2019;4:e001466. doi:10.1136/ 2015.1 PPH—commonly defined as a blood where and how to invest limited resources in bmjgh-2019-001466 loss of 500 mL or more within 24 hours after order to optimise health outcomes. birth—affects about 6% of all women giving Multiple uterotonics have been eval- Handling editor Seye Abimbola birth.1 Uterine atony is the most common uated for PPH prevention over the past Received 4 February 2019 cause of PPH, but it can also be caused by four decades, including oxytocin receptor Revised 10 March 2019 genital tract trauma, retained placental tissue agonists (oxytocin and carbetocin), prosta- Accepted 16 March 2019 or maternal bleeding disorders. The majority glandin analogues (misoprostol, sulprostone, of women who experience PPH have no iden- carboprost), ergot alkaloids (such as ergo- tifiable risk factor, meaning that PPH preven- metrine/methylergometrine) and combina- tion programmes rely on universal use of PPH tions of these (oxytocin plus ergometrine, © Author(s) (or their prophylaxis for all women in the immediate or oxytocin plus misoprostol).
    [Show full text]
  • Oxytocin Carbetocin
    CARBETOCIN To prevent life-threatening pregnanCy CompliCations Postpartum haemorrhage (PPH) is commonly defined as a blood loss of at least 500 ml within 24 hours after birth, and affects about 5% of all women giving birth around the world. Globally, nearly one quarter of all maternal deaths are associated with PPH, and in most low-income countries it is the main cause of maternal mortality. The use of good quality prophylactic uterotonics can avoid the majority of PPH-associated complications during the third stage of labor (the time between the birth of the baby and complete expulsion of the placenta). In settings where oxytocin is unavailable or its quality cannot be guaranteed, the use of other injectable uterotonics (carbetocin, or if appropriate ergometrine/methylergometrine, or oxytocin and ergometrine fixed-dose combination) or oral misoprostol is recommended for the prevention of PPH. The use of carbetocin (100 μg, IM/IV) is recommended for the prevention of PPH for all births in contexts where its cost is comparable to other effective uterotonics. Carbetocin is only recommended for the prevention of postpartum hemorrhage and not recommended for other obstetric indications, such as labor induction, labor augmentation or treatment of PPH. OXYTOCIN Mode of Action CARBETOCIN Synthetic cyclic peptide form of the Long-acting synthetic analogue of naturally occurring posterior oxytocin with agonist properties. pituitary hormone. Binds to oxytocin Binds to oxytocin receptors in the receptors in the uterine myometrium, uterine smooth muscle, resulting in stimulating contraction of this rhythmic contractions, increased uterine smooth muscle by increasing frequency of existing contractions, the sodium permeability of uterine and increased uterine tone.
    [Show full text]
  • University of Birmingham Uterotonic Agents for Preventing Postpartum
    University of Birmingham Uterotonic agents for preventing postpartum haemorrhage Gallos, Ioannis D; Williams, Helen M; Price, Malcolm J; Merriel, Abi; Gee, Harold; Lissauer, David; Moorthy, Vidhya; Tobias, Aurelio; Deeks, Jonathan J; Widmer, Mariana; Tunçalp, Özge; Gülmezoglu, Ahmet Metin; Hofmeyr, G Justus; Coomarasamy, Arri DOI: 10.1002/14651858.CD011689.pub2 License: None: All rights reserved Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Gallos, ID, Williams, HM, Price, MJ, Merriel, A, Gee, H, Lissauer, D, Moorthy, V, Tobias, A, Deeks, JJ, Widmer, M, Tunçalp, Ö, Gülmezoglu, AM, Hofmeyr, GJ & Coomarasamy, A 2018, 'Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis', Cochrane Database of Systematic Reviews, vol. 2018, no. 4, CD011689. https://doi.org/10.1002/14651858.CD011689.pub2 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility:17/05/2018 Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, Moorthy V, Tobias A, Deeks JJ, Widmer M, Tunçalp Ö, Gülmezoglu AM, Hofmeyr GJ, Coomarasamy A. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD011689. DOI: 10.1002/14651858.CD011689.pub2. General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication.
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • Antitumor Effects of Desmopressin in Combination with Chemotherapeutic Agents in a Mouse Model of Breast Cancer GISELLE V
    ANTICANCER RESEARCH 28 : 2607-2612 (2008) Antitumor Effects of Desmopressin in Combination with Chemotherapeutic Agents in a Mouse Model of Breast Cancer GISELLE V. RIPOLL, SANTIAGO GIRON, MARTIN J. KRZYMUSKI, GUILLERMO A. HERMO, DANIEL E. GOMEZ and DANIEL F. ALONSO Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Buenos Aires, Argentina Abstract. The vasopressin peptide analog desmopressin has cytotoxicity on tumor cells, suggesting that the compound been used during surgery to prevent bleeding in patients with modulates a complex biological mechanism on the host coagulation defects. Recent experimental and clinical data which influences tumor spread. We further demonstrated that revealed that perioperative desmopressin therapy can perioperative administration of DDAVP dramatically reduced minimize the spread and survival of residual cancer cells. lymph node and lung metastasis in a model of mammary Here, we explored the antitumor effects of desmopressin in tumor manipulation and surgical excision in mice (6). More combination with chemotherapeutic agents using the F3II recently, a veterinary clinical study showed that perioperative mammary carcinoma in syngeneic Balb/c mice. Intravenous DDAVP prolonged disease-free survival in surgically treated administration of desmopressin at a dose of 2 μg/kg together bitches with locally advanced mammary cancer (7). with weekly cycles of carmustine (20 mg/kg) prevented Breast cancer is one of the most commonly diagnosed primary tumor infiltration of the skin. Combination of malignanc ies in women and mortality for the disease is related desmopressin with paclitaxel (25 mg/kg) significantly reduced to the capacity of breast tumor cells to invade and metastasize. metastatic progression to the lung.
    [Show full text]
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
    [Show full text]
  • The Oxytocin Receptor Gene (OXTR) Is Associated with Autism Spectrum Disorder: a Meta-Analysis
    Molecular Psychiatry (2015) 20, 640–646 © 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15 www.nature.com/mp ORIGINAL ARTICLE The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: a meta-analysis D LoParo and ID Waldman The oxytocin receptor gene (OXTR) has been studied as a risk factor for autism spectrum disorder (ASD) owing to converging evidence from multiple levels of analysis that oxytocin (OXT) has an important role in the regulation of affiliative behavior and social bonding in both nonhuman mammals and humans. Inconsistency in the effect sizes of the OXTR variants included in association studies render it unclear whether OXTR is truly associated with ASD, and, if so, which OXTR single-nucleotide polymorphisms (SNPs) are associated. Thus, a meta-analytic review of extant studies is needed to determine whether OXTR shows association with ASD, and to elucidate which specific SNPs have a significant effect on ASD. The current meta-analysis of 16 OXTR SNPs included 3941 individuals with ASD from 11 independent samples, although analyses of each individual SNP included a subset of this total. We found significant associations between ASD and the SNPs rs7632287, rs237887, rs2268491 and rs2254298. OXTR was also significantly associated with ASD in a gene-based test. The current meta-analysis is the largest and most comprehensive investigation of the association of OXTR with ASD and the findings suggest directions for future studies of the etiology of ASD. Molecular Psychiatry (2015) 20, 640–646; doi:10.1038/mp.2014.77; published online 5 August 2014 INTRODUCTION sizes.8 Nevertheless, several genes and genomic regions have Autism spectrum disorder (ASD) refers to a group of neuro- shown relatively consistent association with ASD.
    [Show full text]
  • Malaysian Statistics on Medicines 2009 & 2010
    MALAYSIAN STATISTICS ON MEDICINES 2009 & 2010 Edited by: Siti Fauziah A., Kamarudin A., Nik Nor Aklima N.O. With contributions from: Faridah Aryani MY., Fatimah AR., Sivasampu S., Rosliza L., Rosaida M.S., Kiew K.K., Tee H.P., Ooi B.P., Ooi E.T., Ghan S.L., Sugendiren S., Ang S.Y., Muhammad Radzi A.H. , Masni M., Muhammad Yazid J., Nurkhodrulnada M.L., Letchumanan G.R.R., Fuziah M.Z., Yong S.L., Mohamed Noor R., Daphne G., Chang K.M., Tan S.M., Sinari S., Lim Y.S., Tan H.J., Goh A.S., Wong S.P., Fong AYY., Zoriah A, Omar I., Amin AN., Lim CTY, Feisul Idzwan M., Azahari R., Khoo E.M., Bavanandan S., Sani Y., Wan Azman W.A., Yusoff M.R., Kasim S., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Suganthi T., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I, Wan Hamilton W.H., Zaridah S., Maisarah A.H., Rohan Malek J., Selvalingam S., Lei C.M., Hazimah H., Zanariah H., Hong Y.H.J., Chan Y.Y., Lin S.N., Sim L.H., Leong K.N., Norhayati N.H.S, Sameerah S.A.R, Rahela A.K., Yuzlina M.Y., Hafizah ZA ., Myat SK., Wan Nazuha W.R, Lim YS,Wong H.S., Rosnawati Y., Ong S.G., Mohd. Shahrir M.S., Hussein H., Mary S.C., Marzida M., Choo Y. M., Nadia A.R., Sapiah S., Mohd. Sufian A., Tan R.Y.L., Norsima Nazifah S., Nurul Faezah M.Y., Raymond A.A., Md.
    [Show full text]
  • Molecular Basis of Ligand Recognition and Activation of Human V2 Vasopressin Receptor
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427077; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular basis of ligand recognition and activation of human V2 vasopressin receptor Fulai Zhou1, 12, Chenyu Ye2, 12, Xiaomin Ma3, 12, Wanchao Yin1, Qingtong Zhou4, Xinheng He1, 5, Xiaokang Zhang6, 7, Tristan I. Croll8, Dehua Yang1, 5, 9, Peiyi Wang3, 10, H. Eric Xu1, 5, 11, Ming-Wei Wang1, 2, 4, 5, 9, 11, Yi Jiang1, 5, 1. The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 2. School of Pharmacy, Fudan University, Shanghai 201203, China 3. Cryo-EM Centre, Southern University of Science and Technology, Shenzhen 515055, China 4. School of Basic Medical Sciences, Fudan University, Shanghai 200032, China 5. University of Chinese Academy of Sciences, 100049 Beijing, China 6. Interdisciplinary Center for Brain Information, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; 7. Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China 8. Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK 9. The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China 10. Department of Biology, Southern University of Science and Technology, Shenzhen 515055, China 11. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China 12. These authors contributed equally: Fulai Zhou, Chenyu Ye, and Xiaomin Ma.
    [Show full text]
  • Influence of Demoxytocin on the Behavioural Actions of Melatonin Manoj G
    Journal of Experimental Sciences 2011, 2(8): 07-09 ISSN: 2218-1768 www.scholarjournals.org www.jexpsciences.com JES-Life Sciences Influence of Demoxytocin on the Behavioural Actions of Melatonin Manoj G. Tyagi* and M. Selva Murugan Department of Pharmacology, Christian Medical College, Vellore 632002, Tamilnadu, India Article Info Abstract Article History Oxytocin is stored and released by the posterior pituitary gland. In this study, the influence of Received : 05-05-2011 oxytocin agonist, demoxytocin pretreatment on the behavioural actions of melatonin was Revised : 27-07-2011 ascertained. Swiss albino mice (n=6) were used for this study as control and test groups. Accepted : 27-07-2011 Demoxytocin was injected in a concentration of (20 I.U/kg, i.p) and melatonin was injected (200μg/kg, i.p) 30 minutes before experimentation. The effect of pretreatment with *Corresponding Author demoxytocin was evaluated after melatonin injection on motor-coordination and locomotor Tel : +91-416-2284237 activity. The results of our study suggest that demoxytocin was not able to affect significantly Fax : +91-416-2284237 the actions on motor co-ordination but attenuated the locomotor activity after melatonin Email: treatment. [email protected] ©ScholarJournals, SSR Introduction Oxytocin has been shown to have a role in social was approved by the Institutional Review Board (IRB) and care separation and related stress. Oxytocin serves important roles of animals was taken as per guidelines of CPCSEA, in behaviour regulation and plays important role in emotional Department of Animal Welfare, Government of India. and social bonding (Landgraf, 1995). Oxytocin receptor is Drugs and Chemicals expressed in the central nervous system and is a G protein Melatonin tablets were obtained from Aristo coupled receptor.
    [Show full text]
  • Traditional Preparations Used As Uterotonics in Sub‐
    International Journal of Gynecology and Obstetrics 120 (2013) 16–22 Contents lists available at SciVerse ScienceDirect International Journal of Gynecology and Obstetrics journal homepage: www.elsevier.com/locate/ijgo REVIEW ARTICLE Traditional preparations used as uterotonics in Sub-Saharan Africa and their pharmacologic effects Vandana Tripathi a,⁎, Cynthia Stanton a, Frank W.J. Anderson b a Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA b Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA article info abstract Article history: Background: Little is known about the use of traditional preparations for uterotonic effects at or near delivery Received 17 March 2012 in Sub-Saharan Africa. Objective: To describe (1) use of traditional preparations in Sub-Saharan Africa Received in revised form 25 June 2012 intended to have uterotonic effects at or near birth; and (2) results of pharmacologic investigations of the Accepted 23 August 2012 uterotonic properties of such preparations. Search strategy: Structured review of 13 databases. Selection criteria: Articles describing use of traditional preparations in Sub-Saharan Africa with primary data, published Keywords: in English between January 1, 1980 and June 30, 2010. Data collection and analysis: Full-text review using Labor augmentation standard spreadsheet templates. Main results: Objective 1 analysis identified 208 plant species used for Pharmacologic effects Plant species uterotonic effects at or near delivery. The most common use was labor induction/augmentation (n=185). Postpartum hemorrhage Other uses were to expel the placenta, shorten the third stage of labor, manage retained placenta (n=61), Retained placenta and prevent/manage postpartum hemorrhage (n=20).
    [Show full text]
  • Tractocile, Atosiban
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tractocile 6.75 mg/0.9 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of 0.9 ml solution contains 6.75 mg atosiban (as acetate). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless solution without particles. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Tractocile is indicated to delay imminent pre-term birth in pregnant adult women with: regular uterine contractions of at least 30 seconds duration at a rate of 4 per 30 minutes a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of 50% a gestational age from 24 until 33 completed weeks a normal foetal heart rate 4.2 Posology and method of administration Posology Treatment with Tractocile should be initiated and maintained by a physician experienced in the treatment of pre-term labour. Tractocile is administered intravenously in three successive stages: an initial bolus dose (6.75 mg), performed with Tractocile 6.75 mg/0.9 ml solution for injection, immediately followed by a continuous high dose infusion (loading infusion 300 micrograms/min) of Tractocile 37.5 mg/5 ml concentrate for solution for infusion during three hours, followed by a lower dose of Tractocile 37.5 mg/5 ml concentrate for solution for infusion (subsequent infusion 100 micrograms/min) up to 45 hours. The duration of the treatment should not exceed 48 hours. The total dose given during a full course of Tractocile therapy should preferably not exceed 330.75 mg of atosiban.
    [Show full text]